Amgen drops Vectibix as colon cancer treatment with Avastin

Amgen halted a clinical trial of its Vectibix drug as part of a chemotherapy regimen with Avastin for treating metastatic colorectal cancer, saying the combo actually hindered survival. The company said an interim analysis of the trial results showed a significant negative response when Vectibix was added to the existing treatment of Genentech's Avastin and chemotherapy.

View Full Article in:

MarketWatch · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID